Making a therapeutic that contains biological components is just the start of creating a medicine. Then, biopharmaceutical companies must capture that drug and ensure that it’s free of contamination.

For decades, therapeutic monoclonal antibody (mAb) production relied on traditional batch-based manufacturing using stainless steel systems. But as biopharmaceutical pipelines grow to meet rising ...